Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Expects to Pocket $83.6M in Stock Placement

NEW YORK, May 19 (GenomeWeb News) - Illumina announced today that it will sell 3.5 million shares of its common stock for $25.50 apiece.


The company expects to receive net proceeds of about $83.6 million from the sale. Illumina last week disclosed its intent to sell the shares, but did not disclose the per-share price. The shares closed down at $25.90 yesterday.


Illumina has granted the underwriters of the offering the right to purchase an additional 525,000 shares of common stock.


Goldman Sachs and Merrill Lynch are acting as joint bookrunning and co-lead managers of the offering, while Cohen and Company and Robert W. Baird are acting as co-managers.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.